HUTCHMED (China) Limited (HCM) is a publicly traded company in the Healthcare — Drug Manufacturers - Specialty & Generic industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
HUTCHMED (China) Limited is a biopharmaceutical firm dedicated to the discovery, advancement, and marketing of innovative targeted and immune-based treatments for various cancers and immune-related disorders. Its operations are divided into two main areas: Oncology/Immunology and a segment encompassing Other Ventures. The company's reach extends from Hong Kong globally.
Is HUTCHMED (China) Limited stock overvalued or undervalued in 2026?
HUTCHMED (China) Limited (HCM) trades at 140× earnings (P/E), against a median of 30.4× across the 246 healthcare companies above $2bn in Kaplio's universe. Note: earnings per share over the last twelve months ($0.10) are far from the consensus for 2027 ($0.46); that is why this range uses expected earnings. No valuation verdict: its earnings are in a dip and too few analysts cover it to know what normal earnings are.
Kaplio overview: HUTCHMED (China) Limited
Market cap $3B · 52 weeks $10 – $16 (17 % below the high) · P/E 140× · 2027 expected P/E 31.3× · Dividend none · Next earnings March 4, 2027 · expected EPS $0.21 · Closing price, Oct 28 · accounts published Jul 30.
- Valuation: P/E 139.5× (no verdict).
- Business: ROIC −2 % (weak).
- Balance sheet: Net cash/EBITDA 0.6× (solid).
- Earnings: 6 of 8 (on track).
What would it be worth at its usual multiples?
No valuation verdict: its earnings are in a dip and too few analysts cover it to know what normal earnings are.
Note: earnings per share over the last twelve months ($0.10) are far from the consensus for 2027 ($0.46); that is why this range uses expected earnings.
What matters in pharma: 2 of 5 pass
- Gross margin 38.7 %, fails.
- FCF / Net Income −19.4 %, fails.
- ROIC −2.2 %, fails.
- R&D / Revenue 29.8 %, passes.
- Net debt / EBITDA −0.6×, passes.
Against its peers (reference peers) — HUTCHMED (China) Limited: P/E 140×; EV/EBITDA —; ROIC -2.1 %; $2.5B. Exelixis, Inc. (P/E 20.8×; EV/EBITDA 15.8×; ROIC 37.9 %; $16.7B), Incyte Corporation (P/E 14.9×; EV/EBITDA 9.6×; ROIC 24.6 %; $23.7B), Genmab A/S (P/E 45.1×; EV/EBITDA 22.4×; ROIC 9.9 %; $35.2B).
Profitability
| Return on Equity | 1.43% |
| Return on Invested Capital | -2.15% |
| Return on Assets | 1.03% |
| Gross Margin | 0.20% |
| Operating Margin | -6.33% |
| Net Margin | 3.26% |
Financial Health
| Debt / Equity | 0.07 |
| Current Ratio | 5.64 |
| Piotroski F-Score | 4 |
| Altman Z-Score | 3.50 |
Price Performance
| 1 month | -5.87% |
| 3 months | +19.68% |
| Year-to-date | -0.08% |
| 1 year | -9.45% |
| 3 years | -34.16% |
| 5 years | -54.72% |
| 10 years | +10.45% |
Related companies: BNTX · INCY · GMAB · EXEL · LEGN · IDYA · ZLAB · RCUS
Explore sector: Healthcare · Drug Manufacturers - Specialty & Generic
More sections of HCM: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks